Go Pro
→ Bank of America: 'Digital Dollar Inevitable' (From Decentralized Masters) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$265.43
+0.1%		$256.73
$190.75
▼
$269.39
$468.57B0.294.01 million shs3.45 million shs
CareDx, Inc. stock logo
CDNA
CareDx
$54.31
-3.9%		$46.88
$13.95
▼
$57.16
$2.92B2.431.07 million shs1.91 million shs
Immunome, Inc. stock logo
IMNM
Immunome
$24.24
-5.9%		$25.47
$10.00
▼
$30.06
$2.92B2.13992,464 shs2.27 million shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$4.27
-5.7%		$4.15
$1.26
▼
$5.78
$747.71M0.21.90 million shs1.66 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.01%+1.11%+0.31%+8.94%+19.09%
CareDx, Inc. stock logo
CDNA
CareDx
-3.86%+1.42%+14.34%+95.01%+248.81%
Immunome, Inc. stock logo
IMNM
Immunome
-5.86%+3.32%-13.46%+24.95%+129.55%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-5.74%+2.40%+3.39%+11.20%+207.19%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
AbbVie Inc. stock logo
ABBV
AbbVie
$265.43
+0.1%		$256.73
$190.75
▼
$269.39
$468.57B0.294.01 million shs3.45 million shs
CareDx, Inc. stock logo
CDNA
CareDx
$54.31
-3.9%		$46.88
$13.95
▼
$57.16
$2.92B2.431.07 million shs1.91 million shs
Immunome, Inc. stock logo
IMNM
Immunome
$24.24
-5.9%		$25.47
$10.00
▼
$30.06
$2.92B2.13992,464 shs2.27 million shs
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$4.27
-5.7%		$4.15
$1.26
▼
$5.78
$747.71M0.21.90 million shs1.66 million shs
7 Blue-Chip Stocks to Add To Your Forever Portfolio Cover
7 Blue-Chip Stocks to Add To Your Forever Portfolio

A strong long-term portfolio starts with companies that can survive recessions, inflation, changing consumer habits, and shifting market leadership.

This report names seven blue-chip stocks across technology, retail, consumer staples, healthcare, networking, sporting goods, and utilities that offer investors a mix of stability, income, growth, and staying power.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
AbbVie Inc. stock logo
ABBV
AbbVie
+0.01%+1.11%+0.31%+8.94%+19.09%
CareDx, Inc. stock logo
CDNA
CareDx
-3.86%+1.42%+14.34%+95.01%+248.81%
Immunome, Inc. stock logo
IMNM
Immunome
-5.86%+3.32%-13.46%+24.95%+129.55%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
-5.74%+2.40%+3.39%+11.20%+207.19%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
AbbVie Inc. stock logo
ABBV
AbbVie
2.88
Moderate Buy$276.644.22% Upside
CareDx, Inc. stock logo
CDNA
CareDx
2.63
Moderate Buy$51.20-5.73% Downside
Immunome, Inc. stock logo
IMNM
Immunome
2.85
Moderate Buy$35.1845.14% Upside
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
2.57
Moderate Buy$6.2345.98% Upside

Current Analyst Ratings Breakdown

Latest IRWD, ABBV, IMNM, and CDNA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/21/2026
Immunome, Inc. stock logo
IMNM
Immunome
Alliance Global Partners logo
Alliance Global Partners
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$32.00
9/16/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Cantor Fitzgerald logo
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingOverweight
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
HSBC Holdings plc logo
HSBC
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetBuy$300.00 ➝ $315.00
9/10/2026
Immunome, Inc. stock logo
IMNM
Immunome
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$40.00
9/8/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Bank of America Corporation logo
Bank of America
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy
9/4/2026
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeHold (C+) ➝ Hold (C)
9/2/2026
CareDx, Inc. stock logo
CDNA
CareDx
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$65.00
9/2/2026
CareDx, Inc. stock logo
CDNA
CareDx
Canaccord Genuity Group Inc. logo
Canaccord Genuity Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$65.00
8/21/2026
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C+)
8/20/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Piper Sandler logo
Piper Sandler
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$298.00 ➝ $303.00
8/17/2026
AbbVie Inc. stock logo
ABBV
AbbVie
Wells Fargo & Company logo
Wells Fargo & Company
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Boost Price TargetOverweight$295.00 ➝ $300.00
(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
AbbVie Inc. stock logo
ABBV
AbbVie
$61.16B7.67$15.16 per share17.51($1.83) per share-145.04
CareDx, Inc. stock logo
CDNA
CareDx
$379.80M7.40$0.01 per share8,672.89$5.89 per share9.22
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/A$5.75 per shareN/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$296.15M2.38$0.24 per share17.58($1.61) per share-2.65
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
AbbVie Inc. stock logo
ABBV
AbbVie
$4.23B$3.5474.9816.441.209.80%-422.07%14.34%10/30/2026 (Estimated)
CareDx, Inc. stock logo
CDNA
CareDx
-$21.35M$2.0726.2486.21N/A24.23%2.87%2.17%11/3/2026 (Estimated)
Immunome, Inc. stock logo
IMNM
Immunome
-$212.39M-$2.53N/AN/AN/AN/A-50.56%-46.93%11/5/2026 (Estimated)
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$24.02M$0.775.55N/AN/A33.36%-58.38%34.93%11/9/2026 (Estimated)

Latest IRWD, ABBV, IMNM, and CDNA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026Q2 2026
Immunome, Inc. stock logo
IMNM
Immunome
-$0.5138-$0.65-$0.1362-$0.65$0.17 millionN/A
8/6/2026Q2 2026
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
$0.32$0.31-$0.01$0.31$114.84 million$113.04 million
7/31/2026Q2 2026
AbbVie Inc. stock logo
ABBV
AbbVie
$3.61$3.65+$0.04$2.03$16.80 billion$16.99 billion
7/30/2026Q2 2026
CareDx, Inc. stock logo
CDNA
CareDx
$0.2321$0.37+$0.1379$2.07$114.05 million$131.95 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
AbbVie Inc. stock logo
ABBV
AbbVie
$6.922.61%+6.80%195.48%53 Years
CareDx, Inc. stock logo
CDNA
CareDx
N/AN/AN/AN/AN/A
Immunome, Inc. stock logo
IMNM
Immunome
N/AN/AN/AN/AN/A
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/AN/AN/AN/AN/A

Latest IRWD, ABBV, IMNM, and CDNA Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
9/10/2026
AbbVie Inc. stock logo
ABBV
AbbVie
quarterly$1.732.71%10/15/202610/15/202611/16/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
AbbVie Inc. stock logo
ABBV
AbbVie
N/A
0.81
0.69
CareDx, Inc. stock logo
CDNA
CareDx
N/A
4.58
4.51
Immunome, Inc. stock logo
IMNM
Immunome
N/A
15.08
15.08
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A
6.06
6.06

Institutional Ownership

CompanyInstitutional Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
70.23%
CareDx, Inc. stock logo
CDNA
CareDx
N/A
Immunome, Inc. stock logo
IMNM
Immunome
44.58%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
N/A

Insider Ownership

CompanyInsider Ownership
AbbVie Inc. stock logo
ABBV
AbbVie
0.06%
CareDx, Inc. stock logo
CDNA
CareDx
2.40%
Immunome, Inc. stock logo
IMNM
Immunome
7.21%
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
9.30%
CompanyEmployeesShares OutstandingFree FloatOptionable
AbbVie Inc. stock logo
ABBV
AbbVie
57,0001.77 billion1.77 billionOptionable
CareDx, Inc. stock logo
CDNA
CareDx
76551.73 million50.49 millionOptionable
Immunome, Inc. stock logo
IMNM
Immunome
177113.58 million105.39 millionOptionable
Ironwood Pharmaceuticals, Inc. stock logo
IRWD
Ironwood Pharmaceuticals
100165.24 million149.87 millionOptionable

Recent News About These Companies

Ironwood Pharmaceuticals, Inc. (IRWD)
September 23 at 6:12 AM  |  finance.yahoo.comhttps://finance.yahoo.com/quote/IRWD/latest-news/
Ironwood Pharmaceuticals (IRWD) is a Top-Ranked Momentum Stock: Should You Buy?
September 21 at 10:50 AM  |  zacks.comhttps://www.zacks.com/stock/news/2992911/ironwood-pharmaceuticals-irwd-is-a-top-ranked-momentum-stock-should-you-buy?cid=cs-stocknewsapi-ft-fundamental_analysis|zacks_education_momentum_score-2992911
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Receives Average Rating of "Moderate Buy" from Brokerages
September 18, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/consensus-ironwood-pharmaceuticals-inc-nasdaq-irwd-receives-average-rating-of-moderate-buy-from-brokerages-2026-09-18/
Ironwood Pharmaceuticals (NASDAQ:IRWD) Stock Passes Above Two Hundred Day Moving Average - Here's What Happened
September 16, 2026  |  americanbankingnews.comhttps://www.americanbankingnews.com/?p=31025885
Ironwood Pharmaceuticals (NASDAQ:IRWD) Shares Pass Above 200-Day Moving Average - Here's Why
September 16, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/price-ironwood-pharmaceuticals-nasdaq-irwd-shares-pass-above-200-day-moving-average-heres-why-2026-09-16/
5 Small Drug Stocks Poised to Benefit From a Biotech Recovery
September 14, 2026  |  zacks.comhttps://www.zacks.com/commentary/2988871/5-small-drug-stocks-poised-to-benefit-from-a-biotech-recovery?cid=cs-stocknewsapi-ft-industry_outlook-2988871
Ironwood: Medicare Is Not The Problem I Thought It Was
September 11, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4945504-ironwood-medicare-is-not-the-problem-i-thought-it-was
508,880 Shares in Ironwood Pharmaceuticals, Inc. $IRWD Bought by Bank of New York Mellon Corp
September 8, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-508880-shares-in-ironwood-pharmaceuticals-inc-irwd-bought-by-bank-of-new-york-mellon-corp-2026-09-08/
Ironwood Pharmaceuticals (NASDAQ:IRWD) Rating Lowered to "Buy" at Wall Street Zen
September 5, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/analyst-ironwood-pharmaceuticals-nasdaq-irwd-rating-lowered-to-buy-at-wall-street-zen-2026-09-05/
Ironwood Pharmaceuticals to Participate in the Wells Fargo 21st Annual Healthcare Conference
September 3, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260903998988/en/ironwood-pharmaceuticals-to-participate-in-the-wells-fargo-21st-annual-healthcare-conference/
Zacks Research Analysts Increase Earnings Estimates for IRWD
September 1, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-analysts-increase-earnings-estimates-for-irwd-2026-09-01/
Zacks Research Has Bullish Outlook for IRWD FY2026 Earnings
August 31, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/estimates-zacks-research-has-bullish-outlook-for-irwd-fy2026-earnings-2026-08-31/
Ironwood Pharmaceuticals: High Dependence On Its Next Trial
August 26, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4940450-ironwood-pharmaceuticals-high-dependence-on-its-next-trial?utm_source=marketbeat.com&utm_medium=referral&feed_item_type=article?source=MarketBeat
Globeflex Capital L P Makes New $1.09 Million Investment in Ironwood Pharmaceuticals, Inc. $IRWD
August 25, 2026  |  marketbeat.comhttps://www.marketbeat.com/instant-alerts/filing-globeflex-capital-l-p-makes-new-109-million-investment-in-ironwood-pharmaceuticals-inc-irwd-2026-08-25/
Ironwood Pharmaceuticals Inc Class A IRWD
August 13, 2026  |  morningstar.comM
Ironwood Q2 Earnings Beat Estimates, Revenues Lag, 2026 View Raised
August 7, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2971308/ironwood-q2-earnings-beat-estimates-revenues-lag-2026-view-raised?cid=cs-stocknewsapi-ft-analyst_blog|earnings_article-2971308
Ironwood Pharmaceuticals’ Earnings Call Highlights LINZESS Surge
August 6, 2026  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/ironwood-pharmaceuticals-earnings-call-highlights-linzess-surge?utm_source=marketbeat.com&utm_medium=referral
Ironwood Pharmaceuticals, Inc. 2026 Q2 - Results - Earnings Call Presentation
August 6, 2026  |  seekingalpha.comhttps://seekingalpha.com/article/4932309-ironwood-pharmaceuticals-inc-2026-q2-results-earnings-call-presentation
Ironwood Pharmaceuticals (IRWD) Q2 Earnings Top Estimates
August 6, 2026  |  zacks.comhttps://www.zacks.com/stock/news/2969902/ironwood-pharmaceuticals-irwd-q2-earnings-top-estimates?cid=cs-stocknewsapi-ft-fundamental_analysis|yseop_template_4-2969902
Ironwood Pharmaceuticals Raises 2026 Full-Year Financial Guidance Building on Strong Second Quarter Results
August 6, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260806795754/en/ironwood-pharmaceuticals-raises-2026-full-year-financial-guidance-building-on-strong-second-quarter-results/
Ironwood Pharmaceuticals to Host Second Quarter 2026 Investor Update Call
July 30, 2026  |  businesswire.comhttps://www.businesswire.com/news/home/20260730260876/en/ironwood-pharmaceuticals-to-host-second-quarter-2026-investor-update-call/

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
NVIDIA logo over a computer chip, server racks, and an upward-trending green stock price chart.
NVIDIA’s Blockbuster Quarter May Still Undersell How Big the AI Buildout Is
By Thomas Hughes | August 27, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Gold-colored concept electric vehicle with a smooth, minimalist body parked outdoors near a building and tree.
Ride-Share Reckoning: Tesla Drives Into Uber's Lane
By Jeffrey Neal Johnson | September 7, 2026
Scientist handles blood sample in lab, symbolizing early cancer detection.
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It
By Bridget Bennett | September 6, 2026
AbbVie stock logo

AbbVie NYSE:ABBV

$265.43 +0.22 (+0.08%)
Closing price 09/23/2026 03:59 PM Eastern
Extended Trading
$266.14 +0.71 (+0.27%)
As of 06:40 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox therapeutic; Vraylar for depressive disorder; Duopa and Duodopa to treat advanced Parkinson's disease; Ubrelvy for the acute treatment of migraine in adults; and Qulipta for episodic and chronic migraine. In addition, the company offers Ozurdex for eye diseases; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; Restasis to increase tear production; and other eye care products. Further, it provides Mavyret/Maviret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; Lupron to treat advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; and Synthroid for hypothyroidism. It has collaborations with Calico Life Sciences LLC; REGENXBIO Inc.; Janssen Biotech, Inc.; and Genentech, Inc., as well as collaboration with Tentarix Biotherapeutics, LP to develop conditionally-active and multi-specific biologics for oncology and immunology. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

CareDx stock logo

CareDx NASDAQ:CDNA

$54.31 -2.18 (-3.86%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$54.42 +0.10 (+0.19%)
As of 04:49 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CareDx, Inc. engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally. It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. The company offers Olerup SSP, which is used to type human leukocyte antigen (HLA) alleles based on sequence specific primer technology; QTYPE that enables precision in HLA typing; and Ottr, a transplant patient management software. In addition, it provides AlloSeq Tx, a high-resolution HLA typing solution; AlloSeq cfDNA, a surveillance solution to measure dd-cfDNA in blood; AlloSeq HCT, a solution for chimerism testing for stem cell transplant recipients; Allocell, a surveillance solution that monitors the level of engraftment and persistence of allogeneic cells for patients who have received cell therapy transplants; and XynQAPI cloud-based transplant quality management software, as well as AlloCare, a mobile app that offers a patient-centric resource for transplant recipients. The company offers its products directly to customers, as well as through third-party distributors and sub-distributors. It has a license agreement with Illumina, Inc. for the distribution, development, and commercialization of NGS products and technologies; and Cibiltech SAS to commercialize iBox, a software for the predictive analysis of post-transplantation kidney allograft loss. The company was formerly known as XDx, Inc. and changed its name to CareDx, Inc. in March 2014. The company was incorporated in 1998 and is headquartered in South San Francisco, California.

Immunome stock logo

Immunome NASDAQ:IMNM

$24.24 -1.51 (-5.86%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$24.31 +0.07 (+0.27%)
As of 04:34 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Immunome, Inc., a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate. Immunome, Inc. was incorporated in 2006 and is based in Bothell, Washington.

Ironwood Pharmaceuticals stock logo

Ironwood Pharmaceuticals NASDAQ:IRWD

$4.27 -0.26 (-5.74%)
Closing price 09/23/2026 04:00 PM Eastern
Extended Trading
$4.26 -0.01 (-0.35%)
As of 06:48 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products. It markets linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation under the LINZESS name in the United States, Mexico, Japan, Saudi Arabia, and China, as well as under the CONSTELLA name in the Canada and European countries. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; Apraglutide, a next-generation, long-acting synthetic peptide analog of glucagon-like peptide-2, as a differentiated therapeutic for rare diseases, including short bowel syndrome dependent on parenteral support and acute graft versus host disease; and CNP-104, an immune nanoparticle for the treatment of primary biliary cholangitis. The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas